FundedIQ
Biotechnology

Stipple Bio: Funding, Investors & Team (Sep 2026)

Stipple Bio is a biotech company that focuses on advancing cellular profiling and target discovery using epitope-level resolution technologies. It develops proprietary platforms that analyze cellular interactions, enabling researchers to identify precise therapeutic targets for drug development. The company’s approach is particularly applied in oncology, where it aims to discover tumor-specific cell surface epitopes to create safer and more effective treatments. Its “Pointillist” platform is designed to map these epitopes with high precision, helping overcome limitations of traditional therapies such as off-target toxicity.

www.stipple.bio LinkedIn Cambridge, United States 11-50 employees
Biopharma Biotechnology Medical Wellness B2B
Total raised
$100M
Rounds
1
Latest
Series A
Apr 2026

Stipple Bio has raised $100M across 1 funding round on record, the most recent a Series A of $100M announced in Apr 2026.

That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

Stipple Bio Company Profile and Key Stats

Total funding raised
$100M
across 1 round on record
Funding rounds on record
1
Latest funding round
Series A
$100M in Apr 2026
Employees
11-50
reported band
Headquarters
Cambridge, United States

Latest funding round on record: Apr 2026.

Stipple Bio Funding Rounds

Date
Round
Amount
Series A
$100M

Stipple Bio Founders and Leadership Team

Name
Role
Contact
Jeff Landau
Founder

No contact details are on record for this team yet.

Stipple Bio Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,182
$8.0M
29,795
$7.5M
8,378
$15M

Stipple Bio's latest round of $100M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like Stipple Bio in Biotechnology and Cambridge

Companies Similar to Stipple Bio

Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…

Series B $65.5M

Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…

Seed $7.0M

ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…

Series C $10.0M

EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…

Series A $35.0M

Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…

Convertible Note $3.5M

Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…

Convertible Note $6.8M

XiltriX North America is an information technology company that specializes in monitoring, predictive…

Undisclosed round $3.0M

Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…

Seed $3.1M

Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…

Series D $66.0M

Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…

Series B $92.7M

Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…

Series C $110M

InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…

Series B $77.0M

Stipple Bio Funding FAQs

What does Stipple Bio do?

Stipple Bio is a biotech company that focuses on advancing cellular profiling and target discovery using epitope-level resolution technologies. It develops proprietary platforms that analyze cellular interactions, enabling researchers to identify precise therapeutic targets for drug development. The company’s approach is particularly applied in oncology, where it aims to discover tumor-specific cell surface epitopes to create safer and more effective treatments. Its “Pointillist” platform is designed to map these epitopes with high precision, helping overcome limitations of traditional therapies such as off-target toxicity.

How much funding has Stipple Bio raised?

Stipple Bio has raised $100M across 1 round on record. The most recent is a Series A of $100M announced in Apr 2026.

When did Stipple Bio last raise funding?

Stipple Bio's most recent funding round on record is a Series A of $100M, announced in Apr 2026.

Who founded Stipple Bio?

FundedIQ lists Jeff Landau (Founder) at Stipple Bio.

Where is Stipple Bio headquartered?

Stipple Bio is based in Cambridge, Massachusetts, United States.

How many employees does Stipple Bio have?

Stipple Bio is in the 11-50 employee band.

How does Stipple Bio's funding compare to other Biotechnology startups?

Stipple Bio's latest round of $100M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.

About FundedIQ's Stipple Bio Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Stipple Bio is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.